Each film-coated tablet contains Atorvastatin (as Calcium) 20 mg or 40 mg.
Pharmacology: Pharmacokinetics: Atorvastatin is rapidly absorbed from the gastro-intestinal tract. It has low absolute bioavailability of about 12% due to presystemic clearance in the gastro-intestinal mucosa and/or first-pass metabolism in the liver, its primary site of action. Atorvastatin is metabolized by cytochrome P450 3A4 to a number of compounds which are also active inhibitors of HMG-CoA reductase. The mean plasma elimination half-life of atorvastatin is about 14 hours although the half-life of inhibitory activity for HMG-CoA reductase is approxiamately 20 to 30 hours due to the contribution of the active metabolites. It is 98% bound to plasma proteins. Atorvastatin is excreted as metabolites, primarily in the bile.
Treatment of hypercholesterolaemias and combined (mixed) hyperlipidaemia.
Initial dose is 10 or 20 mg once daily which may be adjusted at intervals of 4 weeks up to a maximum of 80 mg daily.
Atorvastatin should not be given to patients with acute liver disease or unexplained persistent raised serum-aminotransferase concentrations or to those with porphyria. It should be avoided during pregnancy since there is a possibility that it could interfere with fetal sterol synthesis. It should be used with caution in patients with severe renal impairment.
The commonest adverse effects of therapy with atorvastatin and other statins are gastro-intestinal disturbances. Other adverse effects reported include headache, skin rashes, dizziness, blurred vision, insomnia, and dysgeusia.
Store at temperatures not exceeding 30°C.
C10AA05 - atorvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
FC tab 20 mg x 100's. 40 mg x 100's.